Refractory Multiple Myeloma
Also known as: Multiple Myeloma, Refractory
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00262 | Carmustine | An alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others. |
| DB16738 | Ciltacabtagene autoleucel | A BCMA-directed CAR T-cell therapy used in the treatment of relapsed or refractory multiple myeloma in previously treated patients. |
| DB09331 | Daratumumab | A CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. |
| DB06317 | Elotuzumab | An antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents. |
| DB16665 | Idecabtagene vicleucel | An autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma. |
| DB14811 | Isatuximab | A chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies. |
| DB06603 | Panobinostat | A non-selective histone deacetylase inhibitor used to treat multiple myeloma in combination with other antineoplastic agents. |
| DB11942 | Selinexor | Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated... |
| DB16655 | Teclistamab | A bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager used to treat relapsed and refractory multiple myeloma in adults as monotherapy. |